| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Published online before print May 3, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Division of Therapeutic Proteins, Center for Drug Evaluation & Research, Food and Drug Administration, Bethesda, Maryland; and
Department of Biochemistry and Molecular Biology, University of Medicine and Dentistry of New Jersey, Newark
1Correspondence: FDA-CDER, Division of Therapeutic Proteins, HFM-538, 1401 Rockville Pike, Rockville, MD 20852. E-mail: donnelly{at}cber.fda.gov
Several novel interleukin (IL)-10-related cytokines have recently been discovered. These include IL-22, IL-26, and the interferon-
(IFN-) proteins IFN-1 (IL-29), IFN-2 (IL-28A), and IFN-3 (IL-28B). The ligand-binding chains for IL-22, IL-26, and IFN- are distinct from that used by IL-10; however, all of these cytokines use a common second chain, IL-10 receptor-2 (IL-10R2; CRF2-4), to assemble their active receptor complexes. Thus, IL-10R2 is a shared component in at least four distinct class II cytokine-receptor complexes. IL-10 binds to IL-10R1; IL-22 binds to IL-22R1; IL-26 binds to IL-20R1; and IFN- binds to IFN-R1 (also known as IL-28R). The binding of these ligands to their respective R1 chains induces a conformational change that enables IL-10R2 to interact with the newly formed ligand-receptor complexes. This in turn activates a signal-transduction cascade that results in rapid activation of several transcription factors, particularly signal transducer and activator of transcription (STAT)3 and to a lesser degree, STAT1. Activation by IL-10, IL-22, IL-26, or IFN- can be blocked with neutralizing antibodies to the IL-10R2 chain. Although IL-10R2 is broadly expressed on a wide variety of tissues, only a subset of these tissues expresses the ligand-binding R1 chains. The receptors for these cytokines are often present on cell lines derived from various tumors, including liver, colorectal, and pancreatic carcinomas. Consequently, the receptors for these cytokines may provide novel targets for inhibiting the growth of certain types of cancer.
Key Words: IFN- • STAT3/STAT1 • hepatocytes • 1SGF3 • IL-22BP
This article has been cited by other articles:
|
|
 |
|
  M. Gakovic, J. Ragimbeau, V. Francois, S. N. Constantinescu, and S. Pellegrini The Stat3-activating Tyk2 V678F Mutant Does Not Up-regulate Signaling through the Type I Interferon Receptor but Confers Ligand Hypersensitivity to a Homodimeric Receptor J. Biol. Chem., July 4, 2008; 283(27): 18522 - 18529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wolk, K. Witte, E. Witte, S. Proesch, G. Schulze-Tanzil, K. Nasilowska, J. Thilo, K. Asadullah, W. Sterry, H.-D. Volk, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes J. Leukoc. Biol., May 1, 2008; 83(5): 1181 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhou, O. J. Hamming, N. Ank, S. R. Paludan, A. L. Nielsen, and R. Hartmann Type III Interferon (IFN) Induces a Type I IFN-Like Response in a Restricted Subset of Cells through Signaling Pathways Involving both the Jak-STAT Pathway and the Mitogen-Activated Protein Kinases J. Virol., July 15, 2007; 81(14): 7749 - 7758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ziesche, M. Bachmann, H. Kleinert, J. Pfeilschifter, and H. Muhl The Interleukin-22/STAT3 Pathway Potentiates Expression of Inducible Nitric-oxide Synthase in Human Colon Carcinoma Cells J. Biol. Chem., June 1, 2007; 282(22): 16006 - 16015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Brand, J. Dambacher, F. Beigel, K. Zitzmann, M. H. J. Heeg, T. S. Weiss, T. Prufer, T. Olszak, C. J. Steib, M. Storr, et al. IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro Am J Physiol Gastrointest Liver Physiol, April 1, 2007; 292(4): G1019 - G1028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yang, D. M. Mosser, and X. Zhang Activation of the MAPK, ERK, following Leishmania amazonensis Infection of Macrophages J. Immunol., January 15, 2007; 178(2): 1077 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. El Kasmi, J. Holst, M. Coffre, L. Mielke, A. de Pauw, N. Lhocine, A. M. Smith, R. Rutschman, D. Kaushal, Y. Shen, et al. General Nature of the STAT3-Activated Anti-Inflammatory Response J. Immunol., December 1, 2006; 177(11): 7880 - 7888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Yoon, N. J. Logsdon, F. Sheikh, R. P. Donnelly, and M. R. Walter Conformational Changes Mediate Interleukin-10 Receptor 2 (IL-10R2) Binding to IL-10 and Assembly of the Signaling Complex J. Biol. Chem., November 17, 2006; 281(46): 35088 - 35096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, J. P. Edwards, and D. M. Mosser Dynamic and Transient Remodeling of the Macrophage IL-10 Promoter during Transcription J. Immunol., July 15, 2006; 177(2): 1282 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. D. Mennechet and G. Uze Interferon-{lambda}-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells Blood, June 1, 2006; 107(11): 4417 - 4423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chi, H. L. Dickensheets, K. M. Spann, M. A. Alston, C. Luongo, L. Dumoutier, J. Huang, J.-C. Renauld, S. V. Kotenko, M. Roederer, et al. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J. Virol., May 1, 2006; 80(10): 5032 - 5040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Brand, F. Beigel, T. Olszak, K. Zitzmann, S. T. Eichhorst, J.-M. Otte, H. Diepolder, A. Marquardt, W. Jagla, A. Popp, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G827 - G838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-T. Lin, B. Storer, P. J. Martin, L.-H. Tseng, B. Grogan, P.-J. Chen, L. P. Zhao, and J. A. Hansen Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor {beta} genotype of donor Blood, December 1, 2005; 106(12): 3995 - 4001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Robek, B. S. Boyd, and F. V. Chisari Lambda Interferon Inhibits Hepatitis B and C Virus Replication J. Virol., March 15, 2005; 79(6): 3851 - 3854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Grutz New insights into the molecular mechanism of interleukin-10-mediated immunosuppression J. Leukoc. Biol., January 1, 2005; 77(1): 3 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Srisodsai, R. Kurotani, Y. Chiba, F. Sheikh, H. A. Young, R. P. Donnelly, and S. Kimura Interleukin-10 Induces Uteroglobin-related Protein (UGRP) 1 Gene Expression in Lung Epithelial Cells through Homeodomain Transcription Factor T/EBP/NKX2.1 J. Biol. Chem., December 24, 2004; 279(52): 54358 - 54368. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
